Business
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
Data will be presented demonstrating that therapy with placental-derived mesenchymal-like adherent stem cells (MLASC) results in alterations in gene and
About this update from Celularity Inc.
[{"type":"text","content":"Data will be presented demonstrating that therapy with placental-derived mesenchymal-like adherent stem cells (MLASC) results in alterations in gene and protein signatures associated with inflammation and fistula formation in patients with Crohn’s disease who responded to Celularity’s MLASC treatment\nFLORHAM PARK, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that Adrian Kilcoyne, M.D., M.P.H., M.B.A., Celularity’s Chief Medical Officer, will present data at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy, which will be held May 16-20th in Los Angeles. The title of Dr. Kilcoyne’s abstract is, “Placental-Derived Mesenchymal-Like Adherent Stromal Cell (MLASC) Therapy Results in Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn’s Disease.” “We have had a long interest in the role of cell therapy in autoimmune diseases and look forward to presenting our MLASC data in Crohn’s disease at the upcoming ASGCT annual meeting,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder. “In light of our clinical observations described in a previous release, these data provide a possible mechanism of action leverageable in a broad range of immune-mediated diseases and will help guide the investment decision to progress our novel genetically modified allogeneic placental-derived MLASC, APPL-01, in Crohn’s disease. We believe this cell therapy candidate could make a significant difference as a therapeutic option for patients. Celularity’s unique technology platform is grounded in our use of the post-partum placenta as the source of cells and biomaterials, enabling independent but complementary product opportunities in cellular and regenerative medicine. We’re moving forward with confidence regarding the potential therapeutic benefits of MLASCs as we advance the development of therapeutic options for patients,” said Hariri. About the Poster Presentation Thursday, May 18, 12:00 noon – 2:00 pm Pacific Time, Board No. 1111 Placental-Derived Mesenchymal-Like Adherent Stromal Cell (MLASC) Therapy Results in Alterations in Gene and Protein Signatures Associated with Inflammatio...